A Phase 1 interventional study of LY2439821 in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-05-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 31st largest by enrollment, is one of 5 that started in 2010, is one of 8 in phase 1, and was the 12th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, China, Japan
Ages 18–55 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Germany
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 11 · Phase 4 2
First in 2005; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 164 across the 35 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of LY2439821 subcutaneously administered for 48 weeks in Japanese participants with rheumatoid arthritis who have completed Study I1F-JE-RHAL (NCT01253265).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ambulatory male or female participants.
Exclusion Criteria:
Participants who have any of the following abnormalities of clinical laboratory test results by Week 26 of Study I1F-JE-RHAL (NCT01253265):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
Drug: LY2439821
Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
Drug: LY2439821
Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.
Drug: LY2439821
Administered subcutaneously
Number of Participants With Adverse Events (AEs) [Clinically Significant Events]
Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs). A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.
Time frame: Baseline through study completion (up to Week 56)
| Milestone | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 |
|---|---|---|---|
| Started | 6 | 5 | 17 |
| Completed | 4 | 4 | 14 |
| Not completed | 2 | 1 | 3 |
| Withdrew: Adverse event | 2 | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs). A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.
| participants | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 |
|---|---|---|---|
| AEs (All Causalities) | 6 | 5 | 16 |
| AEs (Drug-Related) | 3 | 4 | 7 |
| SAEs | 1 | 0 | 2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 30 mg LY2439821 | — | 1/6 (16.7%) | 6/6 (100%) |
| 80 mg LY2439821 | — | 0/5 (0%) | 5/5 (100%) |
| 160 mg LY2439821 | — | 2/17 (11.8%) | 16/17 (94.1%) |
| Event | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 |
|---|---|---|---|
| Aortic dissectionVascular disorders | 1/6 | 0/5 | 0/17 |
| Acute myocardial infarctionCardiac disorders | 0/6 | 0/5 | 1/17 |
| CellulitisInfections and infestations | 0/6 | 0/5 | 1/17 |
| Eczema infectedInfections and infestations | 0/6 | 0/5 | 1/17 |
| Event | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 |
|---|---|---|---|
| VomitingGastrointestinal disorders | 2/6 | 0/5 | 0/17 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/6 | 0/5 | 4/17 |
| NasopharyngitisInfections and infestations | 1/6 | 0/5 | 4/17 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/6 | 1/5 | 1/17 |
| Injection site erythemaGeneral disorders | 1/6 | 1/5 | 1/17 |
| Injection site indurationGeneral disorders | 0/6 | 1/5 | 1/17 |
| GastroenteritisInfections and infestations | 0/6 | 1/5 | 0/17 |
| InfluenzaInfections and infestations | 0/6 | 1/5 | 0/17 |
| Systemic mycosisInfections and infestations | 0/6 | 1/5 | 0/17 |
| Tinea pedisInfections and infestations | 0/6 | 1/5 | 1/17 |
All enrolled participants.
| Age, Continuous(years) | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 | Total |
|---|---|---|---|---|
| Mean | 53.2 ± 15.0 | 61.2 ± 8.1 | 57.6 ± 11.4 | 57.3 ± 11.6 |
| Sex: Female, Male(Participants) | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 | Total |
|---|---|---|---|---|
| Female | 3 | 5 | 10 | 18 |
| Male | 3 | 0 | 7 | 10 |
| Ethnicity (NIH/OMB)(Participants) | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 5 | 17 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 | Total |
|---|---|---|---|---|
| Asian | 6 | 5 | 17 | 28 |
| Region of Enrollment(participants) | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 | Total |
|---|---|---|---|---|
| Japan | 6 | 5 | 17 | 28 |
| Weight(kilograms (kg)) | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 | Total |
|---|---|---|---|---|
| Mean | 54.23 ± 9.69 | 54.12 ± 7.66 | 61.25 ± 15.55 | 58.47 ± 13.48 |
| Height(centimeters (cm)) | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 | Total |
|---|---|---|---|---|
| Mean | 161.62 ± 9.62 | 152.34 ± 6.20 | 159.52 ± 8.87 | 158.69 ± 8.90 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m^2)) | 30 mg LY2439821 | 80 mg LY2439821 | 160 mg LY2439821 | Total |
|---|---|---|---|---|
| Mean | 20.68 ± 2.37 | 23.38 ± 3.50 | 23.95 ± 5.28 | 23.15 ± 4.60 |
2 further baseline measures are reported on the registry.
The record gives a start of Dec 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab